Cytek Biosciences Inc Cash Flow Conversion Efficiency
Cytek Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, Cytek Biosciences Inc (CTKB) has a cash flow conversion efficiency ratio of -0.008x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.74 Million) by net assets ($327.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cytek Biosciences Inc (2019–2025)
Cash flow conversion efficiency of Cytek Biosciences Inc from 2019 to 2025. This chart illustrates how Cytek Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CTKB stock price and chart for real-time trading data and today's change.
Cytek Biosciences Inc Cash Flow Conversion Ratio Explained
Cytek Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cytek Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cytek Biosciences Inc ranked by their cash flow conversion efficiency. Also see Cytek Biosciences Inc (CTKB) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Assystem S.A.
PA:ASY
|
0.172x |
|
Complete Logistic Services Bhd
KLSE:5136
|
0.029x |
|
Zhewen Pictures Group Co Ltd
SHG:601599
|
0.048x |
|
P10 Inc
NYSE:PX
|
0.042x |
|
Anhui Province Natural Gas Development Co Ltd
SHG:603689
|
-0.014x |
|
Gujarat State Fertilizers & Chemicals Limited
NSE:GSFC
|
0.036x |
|
Shaanxi Construction Machinery Co Ltd
SHG:600984
|
0.029x |
|
Man Industries (India) Limited
NSE:MANINDS
|
-0.032x |
Annual Cash Flow Conversion Efficiency for Cytek Biosciences Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Cytek Biosciences Inc from 2019 to 2025. Review Cytek Biosciences Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $341.74 Million | $-4.69 Million | -0.014x | -121.38% |
| 2024-12-31 | $395.74 Million | $25.38 Million | 0.064x | +377.33% |
| 2023-12-31 | $393.06 Million | $5.28 Million | 0.013x | +146.75% |
| 2022-12-31 | $425.55 Million | $-12.23 Million | -0.029x | -351.65% |
| 2021-12-31 | $405.38 Million | $4.63 Million | 0.011x | +101.21% |
| 2020-12-31 | $-16.03 Million | $15.16 Million | -0.946x | -386.84% |
| 2019-12-31 | $-41.70 Million | $-13.75 Million | 0.330x | -- |
About Cytek Biosciences Inc
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies usin… Read more